KR930019204A - 활성물질인 플레젤라스틴과 이와 관련된 구조물을 함유하는 투여 에어로졸제 - Google Patents
활성물질인 플레젤라스틴과 이와 관련된 구조물을 함유하는 투여 에어로졸제 Download PDFInfo
- Publication number
- KR930019204A KR930019204A KR1019930003970A KR930003970A KR930019204A KR 930019204 A KR930019204 A KR 930019204A KR 1019930003970 A KR1019930003970 A KR 1019930003970A KR 930003970 A KR930003970 A KR 930003970A KR 930019204 A KR930019204 A KR 930019204A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- suspension stabilizer
- content
- propellant
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 활성물질인 플레젤라스틴, 추진제인 2H-헵타플루오로프로판(TG 227)및/또는 1,,1,2-테트라플루오로에탄(TG 134a)및, 현탁액 안정화제인 TagetRTO TagetRO 및 TagetR02를 함유하는 투여 에어로졸제및 이러한 제형을 제조하는 방법에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 폴리옥시에틸렌-(25)-글리세릴 트리올레에이트(TagetRTO), 폴리옥시에틸렌 -(30)-글리세릴 모노올레 에이트(TagetRO), 폴리옥시에틸렌-(20)-글리세릴 모노올레에이트(TagetRO2), 올레산PluronicRF 68, 탄소수4 내지 10의 과불화카복실신산, 과불화 카복실산의 염, Synperonic형, 과불화 설폰아미도 알콜의 인산 에스테르, 모노아세틸화 모노글리세라이드, 디아세틸화 모노글리세라이드, 인지질 또는 이들 물질의 혼합물이 현탁액 안정화제로서 사용됨을 특징으로 하는, 플레젤라스틴 또는 생리학적으로 허용되는 이의 염, 추진기체 및 현탁액 안정화제를 함유하는 약제학적 조성물.
- 제1항에 있어서, 현탁액 안전화제의 함량이 혼합물의 총중량에 대해 0.01 내지 5중량%인 약제학적 조성물.
- 제1항에 있어서, 현탁액 안전화제의 함량이 혼합물의 총중량에 대해 0.2 내지 2.5중량%인 약제학적 조성물.
- 제1항에 있어서, 현탁액 안전화제의 함량이 혼합물의 총중량에 대해 0.75 내지 1.5중량%인 약제학적 조성물.
- 추진제 또는 추진제 혼합물, 현탁액 안정화제, 임의로 에탄올 및 활성물질을 혼합하고 캔에 충전시킴을 특징으로 하여, 제1항에 따른 약제학적 조성물을 제조하는 방법.
- 제5항에 있어서, 현탁액 안정화제의 함량이 0.01내지 5중량%인 약제학적 조성물을 제조하는 방법.
- 제6항에 있어서, 현탁액 안정화제의 함량이 0.2내지 2.5중량%인 약제학적 조성물을 제조하는 방법.
- 제7항에 있어서, 현탁액 안정화제의 함량이 0.75내지 1.5중량%인 약제학적 조성물을 제조하는 방법.
- 제1항 내지 제4항 중의 어느 한 항에 있어서, 추진제로서 TG 227및/또는 TG 134a를 사용함을 특징으로 하는 약제학적 조성물.
- 제5항 내지 제8항 중의 어느 한 항에 있어서, 추진제로서 TG 227및/또는 TG 134a를 사용함을 특징으로 하는 약제학적 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4208545.4 | 1992-03-17 | ||
DE4208545 | 1992-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR930019204A true KR930019204A (ko) | 1993-10-18 |
Family
ID=6454293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930003970A KR930019204A (ko) | 1992-03-17 | 1993-03-16 | 활성물질인 플레젤라스틴과 이와 관련된 구조물을 함유하는 투여 에어로졸제 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0561166A1 (ko) |
JP (1) | JPH0616539A (ko) |
KR (1) | KR930019204A (ko) |
CN (1) | CN1080852A (ko) |
AU (1) | AU3526193A (ko) |
BR (1) | BR9301172A (ko) |
CA (1) | CA2091713A1 (ko) |
FI (1) | FI931159A (ko) |
HU (1) | HU9300747D0 (ko) |
MX (1) | MX9301410A (ko) |
NO (1) | NO930946L (ko) |
ZA (1) | ZA931875B (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635159A (en) * | 1994-08-26 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing polyglycolyzed glycerides |
GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
RO121172B1 (ro) * | 2001-03-30 | 2007-01-30 | Jago Research Ag | Compoziţie farmaceutică de aerosol şi utilizarea acesteia |
ES2259915B1 (es) * | 2005-03-15 | 2007-12-16 | Laboratorio Aldo-Union, S.A. | Nueva formulacion estable de aerosoles en suspension y procedimiento de obtencion. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE60598T1 (de) * | 1985-11-11 | 1991-02-15 | Asta Pharma Ag | 4-benzyl-1-(2h)-phthalazinon-derivate. |
-
1993
- 1993-02-18 EP EP93102526A patent/EP0561166A1/de not_active Withdrawn
- 1993-03-15 CN CN93102569A patent/CN1080852A/zh active Pending
- 1993-03-15 BR BR9301172A patent/BR9301172A/pt not_active Application Discontinuation
- 1993-03-15 MX MX9301410A patent/MX9301410A/es unknown
- 1993-03-16 HU HU9300747A patent/HU9300747D0/hu unknown
- 1993-03-16 CA CA002091713A patent/CA2091713A1/en not_active Abandoned
- 1993-03-16 AU AU35261/93A patent/AU3526193A/en not_active Abandoned
- 1993-03-16 ZA ZA931875A patent/ZA931875B/xx unknown
- 1993-03-16 JP JP5055296A patent/JPH0616539A/ja active Pending
- 1993-03-16 FI FI931159A patent/FI931159A/fi unknown
- 1993-03-16 KR KR1019930003970A patent/KR930019204A/ko not_active Application Discontinuation
- 1993-03-16 NO NO93930946A patent/NO930946L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CN1080852A (zh) | 1994-01-19 |
FI931159A (fi) | 1993-09-18 |
NO930946D0 (no) | 1993-03-16 |
MX9301410A (es) | 1993-09-01 |
BR9301172A (pt) | 1993-09-21 |
AU3526193A (en) | 1993-09-23 |
HU9300747D0 (en) | 1993-05-28 |
JPH0616539A (ja) | 1994-01-25 |
CA2091713A1 (en) | 1993-09-18 |
FI931159A0 (fi) | 1993-03-16 |
NO930946L (no) | 1993-09-20 |
ZA931875B (en) | 1993-10-06 |
EP0561166A1 (de) | 1993-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0673240B1 (en) | Stabilized medicinal aerosol solution formulations | |
KR100375469B1 (ko) | 약제 | |
EP0927032B1 (en) | Buccal, non-polar spray for nitroglycerin | |
US5508023A (en) | Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant | |
RU2122852C1 (ru) | Состав аэрозоля, находящийся под давлением | |
US4869900A (en) | Pharamaceutical composition containing ubidecarenone | |
DE60312049T2 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff | |
JPH04327527A (ja) | 医薬エアロゾール配合物 | |
JP3950993B2 (ja) | タキサン系の誘導体に基づく製薬組成物 | |
SE8305316D0 (sv) | Topiskt applicerbart preparat | |
US4310543A (en) | Prostaglandin compositions | |
KR970704464A (ko) | 간단한 조성 및 높은 생물 유효성을 갖는 경구 투여용의 신규 사이클로스포린 제형 및 이의 제조방법(Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them) | |
JP2005002123A (ja) | 4,5−エポキシモルヒナン誘導体を含有する安定な医薬品組成物 | |
MX2007011250A (es) | Inhibidor de la cristalizacion y su uso en capsulas de gelatina. | |
KR920700655A (ko) | 주사가능한 클라리트로마이신 조성물 | |
JP2015523401A (ja) | レシニフェラトキシン溶液 | |
US4113751A (en) | Stabilizer for estrogens | |
DE4038203A1 (de) | Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen | |
KR930019204A (ko) | 활성물질인 플레젤라스틴과 이와 관련된 구조물을 함유하는 투여 에어로졸제 | |
AU736539B2 (en) | Method for producing stable acetylsalicylic acid solutions | |
EP0308725A3 (en) | Pharmaceutical composition for intrarectal administration of a calcitonin and unit dosage forms prepared therefrom | |
JPH0157091B2 (ko) | ||
JPH0678227B2 (ja) | 4−エチル−2−ヒドロキシイミノ−5−ニトロ−3−ヘキセンアミド含有製剤用の安定化剤、安定化方法及び安定化された製剤 | |
JPH10330250A (ja) | メナテトレノン油性製剤 | |
JPH08208598A (ja) | プロスタグランジン類組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |